Compare Stocks: ALPN, JAZZ, NBIX, and CORT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALPN Alpine Immune Sciences	$64.97	$64.81	$8.33 ▼ $65.00	$4.46B	0.97	1.92 million shs	N/A
CORT Corcept Therapeutics	$117.17 +2.4%	$94.21	$28.66 ▼ $122.21	$12.37B	0.45	1.27 million shs	540,554 shs
JAZZ Jazz Pharmaceuticals	$248.36 +1.4%	$243.13	$117.10 ▼ $265.05	$15.90B	0.32	817,124 shs	504,864 shs
NBIX Neurocrine Biosciences	$154.49 +1.2%	$167.81	$122.14 ▼ $186.12	$15.52B	0.39	1.47 million shs	1.17 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALPN Alpine Immune Sciences	0.00%	0.00%	0.00%	0.00%	0.00%
CORT Corcept Therapeutics	0.00%	+3.34%	+26.46%	+107.67%	+59.54%
JAZZ Jazz Pharmaceuticals	0.00%	-4.52%	-1.04%	+6.71%	+108.00%
NBIX Neurocrine Biosciences	0.00%	-6.54%	-10.63%	-2.86%	+14.91%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALPN Alpine Immune Sciences	$64.97	$64.81	$8.33 ▼ $65.00	$4.46B	0.97	1.92 million shs	N/A
CORT Corcept Therapeutics	$117.17 +2.4%	$94.21	$28.66 ▼ $122.21	$12.37B	0.45	1.27 million shs	540,554 shs
JAZZ Jazz Pharmaceuticals	$248.36 +1.4%	$243.13	$117.10 ▼ $265.05	$15.90B	0.32	817,124 shs	504,864 shs
NBIX Neurocrine Biosciences	$154.49 +1.2%	$167.81	$122.14 ▼ $186.12	$15.52B	0.39	1.47 million shs	1.17 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALPN Alpine Immune Sciences	0.00%	0.00%	0.00%	0.00%	0.00%
CORT Corcept Therapeutics	0.00%	+3.34%	+26.46%	+107.67%	+59.54%
JAZZ Jazz Pharmaceuticals	0.00%	-4.52%	-1.04%	+6.71%	+108.00%
NBIX Neurocrine Biosciences	0.00%	-6.54%	-10.63%	-2.86%	+14.91%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALPN Alpine Immune Sciences	0.00	N/A	N/A	N/A
CORT Corcept Therapeutics	2.63	Moderate Buy	$119.17	1.70% Upside
JAZZ Jazz Pharmaceuticals	3.00	Buy	$272.89	9.88% Upside
NBIX Neurocrine Biosciences	2.88	Moderate Buy	$200.86	30.02% Upside

Current Analyst Ratings Breakdown

Latest ALPN, JAZZ, NBIX, and CORT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	NBIX Neurocrine Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$196.00 ➝ $182.00
8/11/2026	NBIX Neurocrine Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
8/11/2026	JAZZ Jazz Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$280.00 ➝ $283.00
8/4/2026	JAZZ Jazz Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Buy (B-)
8/4/2026	JAZZ Jazz Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$287.00
8/4/2026	JAZZ Jazz Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$275.00 ➝ $300.00
8/4/2026	JAZZ Jazz Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$254.00 ➝ $264.00
8/4/2026	JAZZ Jazz Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$315.00
8/4/2026	JAZZ Jazz Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$285.00 ➝ $300.00
8/4/2026	JAZZ Jazz Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$275.00
8/4/2026	JAZZ Jazz Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$301.00 ➝ $310.00

(Data available from 8/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALPN Alpine Immune Sciences	$56.52M	78.85	N/A	N/A	$4.85 per share	13.40
CORT Corcept Therapeutics	$830.81M	15.25	$0.92 per share	126.80	$6.16 per share	19.02
JAZZ Jazz Pharmaceuticals	$4.27B	3.78	$16.49 per share	15.06	$71.07 per share	3.49
NBIX Neurocrine Biosciences	$2.86B	5.49	$5.07 per share	30.47	$32.63 per share	4.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALPN Alpine Immune Sciences	-$32.18M	-$0.64	N/A	N/A	N/A	-65.17%	-14.86%	-11.82%	N/A
CORT Corcept Therapeutics	$99.65M	$0.42	278.98	49.86	N/A	6.52%	8.26%	6.45%	11/3/2026 (Estimated)
JAZZ Jazz Pharmaceuticals	-$356.15M	$14.50	17.13	11.15	0.22	20.45%	33.97%	13.02%	11/4/2026 (Estimated)
NBIX Neurocrine Biosciences	$478.60M	$6.82	22.65	15.85	0.67	20.91%	22.43%	15.64%	10/27/2026 (Estimated)

Latest ALPN, JAZZ, NBIX, and CORT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/3/2026	Q2 2026	JAZZ Jazz Pharmaceuticals	$6.18	$5.71	-$0.47	$2.78	$1.11 billion	$1.21 billion
7/31/2026	Q2 2026	NBIX Neurocrine Biosciences	$1.65	$2.85	+$1.20	$1.39	$891.16 million	$959.00 million
7/29/2026	Q2 2026	CORT Corcept Therapeutics	$0.0243	$0.36	+$0.3357	$0.36	$221.15 million	$256.15 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALPN Alpine Immune Sciences	N/A	N/A	N/A	N/A	N/A
CORT Corcept Therapeutics	N/A	N/A	N/A	N/A	N/A
JAZZ Jazz Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NBIX Neurocrine Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALPN Alpine Immune Sciences	N/A	9.56	9.56
CORT Corcept Therapeutics	N/A	2.86	2.77
JAZZ Jazz Pharmaceuticals	0.69	1.78	1.58
NBIX Neurocrine Biosciences	N/A	1.87	1.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALPN Alpine Immune Sciences	75.17%
CORT Corcept Therapeutics	93.61%
JAZZ Jazz Pharmaceuticals	89.14%
NBIX Neurocrine Biosciences	92.59%

Insider Ownership

Company	Insider Ownership
ALPN Alpine Immune Sciences	42.30%
CORT Corcept Therapeutics	20.70%
JAZZ Jazz Pharmaceuticals	4.10%
NBIX Neurocrine Biosciences	4.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALPN Alpine Immune Sciences	142	68.60 million	39.58 million	No Data
CORT Corcept Therapeutics	300	108.10 million	85.72 million	Optionable
JAZZ Jazz Pharmaceuticals	2,890	64.92 million	62.25 million	Optionable
NBIX Neurocrine Biosciences	2,000	101.65 million	96.97 million	Optionable

ALPN, JAZZ, NBIX, and CORT Headlines

Recent News About These Companies

NBIX Stock Dips 12% in a Month: Time to Buy, Hold or Sell?

August 17 at 11:41 AM | zacks.com

Oppenheimer Asset Management Inc. Acquires Shares of 14,783 Neurocrine Biosciences, Inc. $NBIX

August 17 at 5:19 AM | marketbeat.com

S&CO Inc. Makes New Investment in Neurocrine Biosciences, Inc. $NBIX

August 16 at 6:55 AM | marketbeat.com

Focus Partners Advisor Solutions LLC Invests $1.93 Million in Neurocrine Biosciences, Inc. $NBIX

August 16 at 4:39 AM | marketbeat.com

14,787 Shares in Neurocrine Biosciences, Inc. $NBIX Purchased by ABN AMRO Bank N.V.

August 16 at 3:03 AM | marketbeat.com

Summit Global Investments Invests $4.96 Million in Neurocrine Biosciences, Inc. $NBIX

August 15 at 6:55 AM | marketbeat.com

Morgan Stanley Has Lowered Expectations for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price

August 13, 2026 | marketbeat.com

NBIX stock slips as $2.9B Soleno deal triggers fresh drug safety warnings

August 13, 2026 | msn.com

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Average Recommendation of "Moderate Buy" from Analysts

August 13, 2026 | americanbankingnews.com

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Consensus Rating of "Moderate Buy" by Brokerages

August 13, 2026 | marketbeat.com

What's going on with Neurocrine Biosciences stock on Wednesday?

August 12, 2026 | msn.com

Why Neurocrine Biosciences (NBIX) Stock Is Down Today

August 12, 2026 | quiverquant.comQ

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily ...

August 12, 2026 | aol.comA

Neurocrine Biosciences shares fall amid Vykat safety concerns

August 12, 2026 | msn.com

Neurocrine slips as safety issues linked to Vykat XR resurface

August 12, 2026 | seekingalpha.com

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia

August 12, 2026 | prnewswire.com

Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug

August 12, 2026 | reuters.com

Handelsbanken Fonder AB Has $34.70 Million Holdings in Neurocrine Biosciences, Inc. $NBIX

August 12, 2026 | marketbeat.com

Bank of America Corp DE Boosts Holdings in Neurocrine Biosciences, Inc. $NBIX

August 10, 2026 | marketbeat.com

Assenagon Asset Management S.A. Has $37.52 Million Holdings in Neurocrine Biosciences, Inc. $NBIX

August 9, 2026 | marketbeat.com

Neurocrine Biosciences (NASDAQ:NBIX) Lowered to Hold Rating by Wall Street Zen

August 9, 2026 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALPN, JAZZ, NBIX, and CORT Company Descriptions

Alpine Immune Sciences NASDAQ:ALPN

Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.

Corcept Therapeutics NASDAQ:CORT

$117.17 +2.70 (+2.36%)

As of 04:00 PM Eastern

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Jazz Pharmaceuticals NASDAQ:JAZZ

$248.36 +3.40 (+1.39%)

As of 04:00 PM Eastern

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Neurocrine Biosciences NASDAQ:NBIX

$154.49 +1.77 (+1.16%)

As of 04:00 PM Eastern

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALPN, JAZZ, NBIX, and CORT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALPN, JAZZ, NBIX, and CORT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALPN, JAZZ, NBIX, and CORT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALPN, JAZZ, NBIX, and CORT Company Descriptions

Alpine Immune Sciences NASDAQ:ALPN

Corcept Therapeutics NASDAQ:CORT

Jazz Pharmaceuticals NASDAQ:JAZZ

Neurocrine Biosciences NASDAQ:NBIX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALPN, JAZZ, NBIX, and CORT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALPN, JAZZ, NBIX, and CORT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALPN, JAZZ, NBIX, and CORT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALPN, JAZZ, NBIX, and CORT Company Descriptions

Alpine Immune Sciences NASDAQ:ALPN

Corcept Therapeutics NASDAQ:CORT

Jazz Pharmaceuticals NASDAQ:JAZZ

Neurocrine Biosciences NASDAQ:NBIX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools